


Journal Pre-proof

The Consequences Of COVID-19 Pandemic On Patients With Monoclonal Gammopathy Associated Systemic Capillary-Leak Syndrome (Clarkson's disease)

Marc Pineton de Chambrun, MD, MSc, Quentin Moyon, MD, MSc, Stanislas Faguer, MD, PhD, Geoffrey Urbanski, MD, MSc, Alexis Mathian, MD, PhD, Noémie Zucman, MD, Marie Werner, MD, Charles-Edouard Luyt, MD, PhD, Franco Verlicchi, MD, Zahir Amoura, MD, MSc, for the EurêClark Study Group



PII: S2213-2198(21)01359-3

DOI: <https://doi.org/10.1016/j.jaip.2021.11.023>

Reference: JAIP 3984

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 19 August 2021

Revised Date: 19 November 2021

Accepted Date: 19 November 2021

Please cite this article as: Pineton de Chambrun M, Moyon Q, Faguer S, Urbanski G, Mathian A, Zucman N, Werner M, Luyt CE, Verlicchi F, Amoura Z, for the EurêClark Study Group, The Consequences Of COVID-19 Pandemic On Patients With Monoclonal Gammopathy Associated Systemic Capillary-Leak Syndrome (Clarkson's disease), *The Journal of Allergy and Clinical Immunology: In Practice* (2022), doi: <https://doi.org/10.1016/j.jaip.2021.11.023>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

TITLE: The Consequences Of COVID-19 Pandemic On Patients With Monoclonal Gammopathy
Associated Systemic Capillary-Leak Syndrome (Clarkson's disease)

RUNNING TITLE: Consequences Of COVID-19 Pandemic In Clarkson's disease

AUTHORS: Marc Pineton de Chambrun^{1,2,3}, MD, MSc; Quentin Moyon^{1,3}, MD, MSc; Stanislas Faguer⁴, MD, PhD; Geoffrey Urbanski⁵, MD, MSc; Alexis Mathian³, MD, PhD; Noémie Zucman⁶, MD; Marie Werner⁷, MD; Charles-Edouard Luyt^{1,2}, MD, PhD; Franco Verlicchi⁸, MD; Zahir Amoura³, MD, MSc for the EurêClark Study Group.

AUTHOR AFFILIATIONS: ¹Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France; ²Sorbonne Université, INSERM, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France ; ³Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; ⁴Département de Néphrologie Et Transplantation D'organes, Centre de Référence Des Maladies Rénales Rares, INSERM U1297 (I2MC, équipe 12), Centre Hospitalier Universitaire de Toulouse, Toulouse, France; ⁵Service de Médecine Interne et d'Immunologie Clinique, Centre Hospitalier Universitaire, Angers, France; ⁶Université de Paris, APHP, DMU ESPRIT, Service de Médecine Intensive Réanimation, Hôpital Louis Mourier, Colombes, France; ⁷Université Paris Saclay, AP-HP, Hôpital Bicêtre, Service de réanimation chirurgicale adulte, Le Kremlin-Bicêtre, France; ⁸Transfusion Service, Romagna Local Health Unit, Ravenna, Italy.

Correspondence and requests for reprints should be addressed to Marc Pineton de Chambrun, MD, MSc, Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France; E-mail: marc.dechambrun@gmail.com; marc.pinetondechambrun@aphp.fr Tel: +33 (0)1 84 82 76 32, +33 (0)1 42 16 38 16

Word count: 979/1000

Table count: 2

References: 7

Key words: systemic capillary-leak syndrome; COVID-19; Clarkson's disease; vaccination

Competing interest: all authors certify they have no conflict of interest to disclose

Funding: none

Acknowledgment: none

Patients and Public involvement in the research: none

Clinical Implications box: SARS-CoV-2 infection and COVID-19 vaccination can trigger severe relapse of systemic capillary-leak syndrome (SCLS, Clarkson's disease).

The systemic capillary-leak syndrome (SCLS), also known as Clarkson's disease, is a rare condition characterized by recurrent life-threatening episodes of capillary hyperpermeability in the presence of a monoclonal gammopathy. Viral infections, especially influenza virus, are known to reveal the disease and to elicit its recurrence¹⁻³. Patients are asymptomatic between episodes. Monoclonal gammopathy of undetermined significance occurs in 3.2% of persons 50 years of age or older and in 5.3% of those 70 years of age or older⁴. However, the incidence and prevalence of Clarkson's disease in this population is unknown, certainly very low¹. The prevention of severe episodes rely on chronic perfusion of high-dose intravenous immunoglobulins (IVIg)⁵. Aside IVIg and a modest effect of terbutaline, no other treatment have shown to prevent recurrence. Moreover, despite some promising drugs, none have been proven effective in reducing capillary-leak during severe episodes. Several pathophysiological pathways, such as phosphodiesterase inhibition, are candidate for the treatment of severe episodes.

The coronavirus disease 2019 (COVID-19) and its preventive vaccines have been recently reported to trigger Clarkson's disease first episodes and relapses^{6,7}. We aimed to describe the outcome of European patients with Clarkson's disease from the EurêClark Registry during the COVID-19 pandemic. All patients with a diagnosis of monoclonal gammopathy-associated SCLS included in the EurêClark Registry and alive at the start of COVID-19 pandemic (February 1st 2020), were included and evaluated until July 10th 2021 (**Table 1**). Thirty patients were included, with a female-to-male ratio 1.3 and a mean±SD age 58±14 years. Every patient had an IgG gammopathy with kappa (n=24) or lambda light chain (n=7). Most patients were under long-term treatment with intravenous immunoglobulins (n=27, 90%). Five patients (17%) experienced a relapse related to a proven (n=3) or highly probable (see Table 1 footnotes) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with a fatal outcome in 4 patients. None had evidence of COVID-19 pneumonia and all experienced typical flare of Clarkson's disease with severe hypovolemic shock and refractory multiple organ failure. Twenty patients underwent COVID-19 vaccination with: BNT162b2 (Pfizer-BioNTech) n=17; Ad26.COV2.S (Janssen) n=1; and mRNA-1273 (Moderna) n=2. Vaccination was uneventful in 18

patients, including two not receiving IVIg. Two patients treated with IVIg had a relapse after a second dose mRNA vaccine, with favorable outcome in both cases. During the time of the study, 5 patients had a new diagnosis Clarkson's disease and were reported to the EurêClark Registry (**Table 2**). All required intensive care unit management, and one died during this opening episode. Four had their first flare triggered by a PCR-confirmed COVID-19 infection. The last patient, previously known to have a monoclonal gammopathy, had a typical opening flare of SCLS 3 days after the first injection of ChAdOx1 (AstraZeneca).

Our results highlight the burden of COVID-19 pandemic for patients with Clarkson's disease. They face the threat of both the infection and its preventive vaccine. Moreover, IVIg seems to protect them imperfectly against these foes. Several lessons can be drawn from our results jointly with previous reports. First, COVID-19 infection seems to induce very frequently a relapse of Clarkson's. Every patient from our cohort with a proven or suspected SARS-CoV-2 infection had a severe flare, fatal in 80% of cases. To the best of our knowledge and in the published literature, there are no report of uneventful SARS-CoV-2 infection in these patients. As previously reported, viral infection frequently elicit relapse in Clarkson's disease patients. However, vascular leakage seems to play a major role in COVID-19 pathophysiology and may explain the high relapse risk during SARS-CoV-2 infection. While IVIg have been shown to prevent severe episodes⁸ and to improve survival⁵, they failed to prevent the COVID-19-related relapses in 4 of our patients, including one treated at full dose (2g/kg/4 weeks). The tapered dose in the 3 others might have lowered their preventive effect. The lack of SARS-CoV-2 specific immunoglobulins in available preparations of IVIg could explain this lower efficacy⁶. A recent study revealed the apparition of anti-SARS-CoV-2 NP and S-RBD antibodies in IVIg preparation containing plasma collected in Italy after March 2020⁹. Yet, it cannot be denied that some patients from our cohort might have had asymptomatic COVID-19 during the time of the study. Second, while the incidence of Clarkson's disease is unknown, being probably very low, this pandemic has been associated with an elevated number of new diagnosis in a short period of time. This findings highlights the critical role of viral triggers in the onset of SCLS. Third, while we usually

recommended vaccination in our patients (especially against influenzae virus), COVID-19 vaccines have been shown to trigger Clarkson's disease episodes. All four vaccines authorised by the European Medicines Agency (EMA, BNT162b2, Ad26.COV2.S, mRNA-1273 and ChAdOx1) have been incriminated and not solely the ChAdOx1 (AstraZeneca) for which this adverse effect was recently pointed out by the EMA's safety committee. Conversely with cases reported by Kirk M. Druey's team⁷, our 2 patients relapsing after vaccination were given IVIg regularly. Furthermore, 18 patients, including 2 not receiving IVIg had no adverse event after COVID-19 vaccination.

This study has several strengths and limitations. First, the small sample size of this series should be put in perspective with the rarity of the disease. Second, while the retrospective nature of this work is inevitably associated with selection bias, most information originates from prospectively collected data. Third, only symptomatic episodes after vaccination were monitored but not any other vaccine adverse reactions. Last, we did not evaluate the anti-spike antibody response to confirm that vaccination participates in Clarkson's disease relapse prevention. In conclusion, COVID-19 pandemic has serious consequences in SCLS patients. SARS-CoV-2 infection is associated with a high risk of relapse and all COVID-19 vaccines can trigger episodes. High-dose IVIg remains the only effective preventive treatment and should not be stopped during the pandemic. In our opinion, the benefit/risk ratio favors COVID-19 vaccination in our patients under IVIg, but further data is needed to determine its safest modalities.

1 REFERENCES

- 2 1. Druey KM, Parikh SM. Idiopathic systemic capillary leak syndrome (Clarkson disease). *J Allergy*
3 *Clin Immunol.* 2017;140:663–70.
- 4 2. Pineton de Chambrun M, Luyt C-E, Beloncle F, Gousseff M, Mauhin W, Argaud L, et al. The
5 Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission.
6 *Crit Care Med.* 2017;45:1216–23.
- 7 3. Pineton de Chambrun M, Mathian A, Luyt C-E, Combes A, Amoura Z, EurêClark Study Group.
8 Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe
9 episodes. *J Allergy Clin Immunol.* 2018;141:1539–40.
- 10 4. Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-Term Follow-up
11 of Monoclonal Gammopathy of Undetermined Significance. *N Engl J Med.* 2018;378:241–9.
- 12 5. Pineton de Chambrun M, Gousseff M, Mauhin W, Lega J-C, Lambert M, Rivière S, et al.
13 Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated
14 Systemic Capillary-Leak Syndrome. *Am J Med.* 2017;130:1219.e19-1219.e27.
- 15 6. Pineton de Chambrun M, Cohen-Aubart F, Donker DW, Cariou P-L, Luyt C-E, Combes A, et al.
16 SARS-CoV-2 Induces Acute and Refractory Relapse of Systemic Capillary Leak Syndrome
17 (Clarkson's Disease). *The American Journal of Medicine [Internet].* 2020; Available from:
18 <http://www.sciencedirect.com/science/article/pii/S0002934320303739>
- 19 7. Matheny M, Maleque N, Channell N, Eisch AR, Auld SC, Banerji A, et al. Severe Exacerbations of
20 Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series. *Ann Intern Med.*
21 2021;
- 22 8. Gousseff M, Arnaud L, Lambert M, Hot A, Hamidou M, Duhaut P, et al. The systemic capillary leak
23 syndrome: a case series of 28 patients from a European registry. *Ann Intern Med.* 2011;154:464–
24 71.
- 25 9. Pisani G, Cristiano K, Simeoni M, Martina A, Pati I, Carocci A, et al. Detection of antibodies
26 against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous

immunoglobulins produced from plasma collected in Italy during the pandemic. Blood Transfus.
2021;

EURÊCLARK STUDY GROUP

PINETON de CHAMBRUN Marc^{1,49}, GOUSSEFF Marie², MAUHIN Wladimir¹, HOT Arnaud³, LEGA Jean-Christophe⁵, LAMBERT Marc⁴, RIVIERE Sophie⁶, DOSSIER Antoine⁷, RUIVARD Marc⁸, LHOTE François⁹, BLAISON Gilles¹⁰, MERCERON Sybille¹¹, ZAPPELLA Nathalie¹¹, ALRIC Laurent¹², AGARD Christian¹³, Mathieu LACOUT¹³, SAADOUN David¹⁴, GRAVELEAU Julie¹⁵, SOUBRIER Martin¹⁶, HAROCHE Julien¹, BOILEAU Julien¹⁷, LUCCHINI LECOMTE Marie-Josée¹⁸, HANSLIK Thomas¹⁹, CHRISTIDES Christine²⁰, LEVESQUE Hervé²¹, TALASCZKA Aline²², BULTE Caroline²¹, HACHULLA Eric⁴, DECAUX Olivier²³, SONNEVILLE Romain⁷, IBOUANGA Florent²⁴, ARNULF Bertrand²⁵, BENEDIT Marcel²⁶, VIALARD Jean François²⁷, TIEULIE Nathalie²⁸, HADDAD Fadi²⁹, MOULIN Bruno³⁰, COHEN-AUBERT Fleur¹, LOVEY Pierre-Yves³¹, LE MOAL Sylvie³², BIBES Béatrice³³, RIVARD Georges-Etienne³⁴, RONDEAU Eric³⁵, MALIZIA Giuseppe³⁶, DEBOURDEAU Philippe³⁷, ABGUEGUEN Pierre³⁸, BOSSERAY Annick³⁹, DEVAQUET Jérôme⁴⁰, PRESNE Claire⁴¹, LIFERMAN François⁴², LIMAL Nicolas⁴³, ARGAUD Laurent⁴⁴, HERNU Romain⁴⁴, DE LA SALLE Sylvie⁴⁴, FAGUER Stanislas⁴⁵, URBANSKI Geoffrey⁴⁶, ZUCMAN Noémie⁴⁷, WERNER Marie⁴⁸, LUYT Charles-Edouard⁴⁹, MOYON Quentin^{1,49}, VERLICCHI Franco⁵⁰, TRONCOSO Jorge Álvarez⁵¹, HARTY John⁵², GODMER Pascal², HIE Miguel¹, PAPO Thomas⁷, HATRON Pierre-Yves⁴, MATHIAN Alexis¹, AMOURA Zahir¹

¹Service de médecine interne 2, CHU La Pitié-Salpêtrière, APHP, Paris, France

²Service de médecine interne, CH Bretagne Atlantique, Vannes, France

³Service de médecine interne, CHU Edouard Herriot, Lyon, France

⁴Service de médecine interne, Hôpital Claude Huriez, CHRU Lille, France

⁵Service de médecine interne et vasculaire, CHU Lyon Sud, France

⁶Service de médecine interne, Hôpital St-Eloi, CHRU Montpellier, France

⁷Service de médecine interne, CHU Bichat, Paris, APHP, France

⁸Service de médecine interne, Hôpital d'Estaing, CHU de Clermont-Ferrand, France

⁹Service de médecine interne, Hôpital Delafontaine, Saint-Denis, France

- 1 ¹⁰Service de médecine interne et rhumatologie, Hôpital Pasteur, Colmar, France
- 2 ¹¹Service de réanimation polyvalente, CH André Mignot, Versailles, France
- 3 ¹²Service de médecine interne, Pôle digestif, CHU Purpan, Toulouse, France
- 4 ¹³Service de médecine interne, CHU Hôtel-Dieu, Nantes, France
- 5 ¹⁴Service de médecine interne et immunologie clinique, CHU La Pitié-Salpêtrière, APHP, Paris, France
- 6 ¹⁵Service de médecine polyvalente, CH S^t-Nazaire, France
- 7 ¹⁶Service de rhumatologie, Hôpital Gabriel-Montpied, CHU Clermont-Ferrand, France
- 8 ¹⁷Service de médecine interne, CH Morlaix, France
- 9 ¹⁸Service de médecine Interne, CH Notre-Dame de la Miséricorde, Ajaccio, France
- 10 ¹⁹Service de médecine interne, CHU Ambroise Paré, Boulogne-Billancourt, France
- 11 ²⁰Service de médecine interne, CH Avignon, France
- 12 ²¹Service de médecine interne, Hôpital de Bois-Guillaume, CHU de Rouen, France
- 13 ²²Service de médecine interne, CH Roubaix, France
- 14 ²³Service de médecine interne, Hôpital Pontchaillou, CHU Rennes, France
- 15 ²⁴Service de médecine Interne, CH S^t-Omer, France
- 16 ²⁵Service d'immunologie clinique, CHU S^t-Louis, Paris, APHP, France
- 17 ²⁶Service de réanimation polyvalente, CH Moulins, France
- 18 ²⁷Service de médecine interne, Hôpital Haut-Lévêque, CHU Bordeaux Sud, Pessac, France
- 19 ²⁸Service de rhumatologie, Hôpital Pasteur 2, CHU Nice, France
- 20 ²⁹Service de médecine interne, Hôtel-Dieu de France, Beyrouth, Liban
- 21 ³⁰Service de néphrologie dialyse transplantation rénale, Hôpital Civil, CHU de Strasbourg, France
- 22 ³¹ Service d'hématologie, CH Sion, Suisse
- 23 ³²Service de médecine interne, CH de S^t-Brieuc, France
- 24 ³³Service de médecine interne, CHP S^t-Grégoire, France
- 25 ³⁴Service d'hématologie, CHU S^{te}-Justine, Montréal, Canada
- 26 ³⁵Service d'urgences néphrologiques et de transplantation rénale, CHU Tenon, France

- 1 ³⁶Divisione di Medicina, Ospedale V. Cervello, Palermo, Italy
- 2 ³⁷Institut Sainte-Catherine, Avignon, France
- 3 ³⁸Service des maladies infectieuses et tropicales, CHU d'Angers, Angers, France
- 4 ³⁹Service de médecine interne, CHU Grenoble Alpes, France
- 5 ⁴⁰Service de réanimation polyvalente, CH Foch, Suresnes, France
- 6 ⁴¹Service de néphrologie, Hôpital sud, CHU Amiens, Salouël, France
- 7 ⁴²Service de médecine interne, CH Dax, France
- 8 ⁴³Service de médecine interne, CHU Henri Mondor, APHP, Créteil, France
- 9 ⁴⁴Service de réanimation médicale, CHU Edouard Herriot, Lyon, France
- 10 ⁴⁵Département de Néphrologie Et Transplantation D'organes, CHU de Toulouse, Toulouse, France
- 11 ⁴⁶Service de Médecine Interne et d'Immunologie Clinique, CHU d'Angers, Angers, France
- 12 ⁴⁷Service de Médecine Intensive Réanimation, Hôpital Louis Mourier, Colombes, France
- 13 ⁴⁸Service de réanimation chirurgicale adulte, Le Kremlin-Bicêtre, France
- 14 ⁴⁹Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, Paris, France
- 15 ⁵⁰Transfusion Service, Romagna Local Health Unit, Ravenna, Italy
- 16 ⁵¹Medicina Interna, Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario La Paz-
17 Cantoblanco-Carlos III, Madrid, Espana
- 18 ⁵²Daisy Hill Hospital, Newry, Northern Ireland

Table 1. Consequences and outcome of patients with known Clarkson's disease during the COVID-19 pandemic (2020-2021)

Patients	Sex	Age	Diagnosis	Monoclonal Gammopathy	IVIg	Date	Dose	Covid-19	Covid-19 vaccine	Flare	Interval ¹	ICU ²	Outcome
1	F	45	2013	IgG K	1	2013	0.5g/kg/4w	PCR +	-	Yes	Concomitant	Yes	Dead
2	M	62	2015	IgG K	1	2015	2g/kg/4w	-	BNT162b2	No	-	-	Alive
3	M	53	2010	IgG K	1	2011	0.5g/kg/4w	-	BNT162b2	No	-	-	Alive
4	F	81	2012	IgG K & L	1	2012	0.5g/kg/12w	-	BNT162b2	No	-	-	Alive
5	M	76	2004	IgG K	1	2021	1g/kg/4w	-	-	No	-	-	Alive
6	M	75	2007	IgG L	1	2009	0.5g/kg/16w	-	BNT162b2	No	-	-	Alive
7	M	56	2010	IgG K	1	2010	1g/kg/4w	PCR +	-	Yes	Concomitant	Yes	Alive
8	F	54	2008	IgG L	1	2008	0.5g/kg/6w	Probable ³	-	Yes	Concomitant	Yes	Dead
9	M	61	2011	IgG K	1	2012	0.7g/kg/6w	-	BNT162b2	No	-	-	Alive
10	M	67	2003	IgG K	1	2005	2g/kg/4w	-	BNT162b2	No	-	-	Alive
11	F	81	2013	IgG K	1	2014	0.5g/kg/6w	-	BNT162b2	No	-	-	Alive
12	F	80	2013	IgG K	1	2014	1g/kg/4w	-	BNT162b2	No	-	-	Alive
13	F	59	2009	IgG K	0	-	-	-	BNT162b2	No	-	-	Alive
14	F	62	2002	IgG K	1	2007	1g/kg/8w	-	mRNA-1273	No	-	-	Alive
15	F	73	2011	IgG L	1	2011	2g/kg/6w	-	BNT162b2	No	-	-	Alive

16	M	73	2015	IgG L	1	2015	0.5g/kg/8w	-	Ad26.COV2.S	No	-	-	Alive
17	M	51	2008	IgG K	1	2008	1g/kg/4w	-	-	No	-	-	Alive
18	F	68	2016	IgG L	1	2016	0.5g/kg/4w	-	-	No	-	-	Alive
19	F	59	2008	IgG K	1	2008	0.5g/kg/4w	-	BNT162b2	No	-	-	Alive
20	M	59	2012	IgG K	1	2012	2g/kg/4w	PCR +	-	Yes	Concomitant	Yes	Dead
21	F	40	2017	IgG K	1	2018	1g/kg/4w	-	BNT162b2	No	-	-	Alive
22	F	46	2016	IgG K	1	2019	0.5g/kg/4w	-	BNT162b2	Yes	2d after 2 nd dose	No	Alive
23	F	52	2018	IgG K	0	-	-	-	BNT162b2	No	-	-	Alive
24	F	61	2003	IgG K	0	-	-	Probable ³	-	Yes	Concomitant	Yes	Dead
25	M	43	2021	IgG L	1	2021	2g/kg/4w	-	BNT162b2	No	-	-	Alive
26	M	45	2020	IgG K	1	2021	2g/kg/4w	-	BNT162b2	No	-	-	Alive
27	M	60	2019	IgG K	1	2019	1g/kg/3w	-	BNT162b2	No	-	-	Alive
28	F	27	2021	IgG K	1	2021	2g/kg/4w	-	-	No	-	-	Alive
29	F	37	2016	IgG K	1	2016	1g/kg/4w	-	mRNA-1273	Yes	3d after 2 nd dose	Yes	Alive
30	F	43	2011	IgG K	1	2011	1g/kg/6w	-	-	No	-	-	Alive

EurêClark Registry was approved by local review boards and by the Commission Nationale de l'Informatique et des Libertés n°1001704; no AP-HP 14 in 1997.

Abbreviation: COVID-19, the coronavirus disease 2019; M, male; F, female; IgG, G immunoglobulin; K, kappa light chain; L, lambda light chain; g/kg/w, gram per kilogram of body weight delivered every x weeks; PCR, polymerase-chain reaction; d, days; ICU, intensive care unit.

¹Interval between COVID-19 infection or COVID-19 vaccination and Clarkson's disease flare.

²Admission to the ICU.

³Two patients died during severe flare of Clarkson's disease complicated by refractory cardiac arrest probably related to an undiagnosed COVID-19 infection. Both had fever and viral symptoms upon emergency department admission which happened respectively during the epidemic peak of the first wave in France (March 23, 2020) and of the third wave in Italy (March 5, 2021). As cardiac arrest occurred very early in both patients, deep airway COVID-19 PCR could not be taken.

Table 2. New diagnosis of Clarkson's disease during the COVID-19 pandemic (2020-2021)

Patients	Sex	Age, years	Monoclonal Gammopathy	Covid-19	Covid-19 vaccine	Flare	Interval ¹	ICU ²	Hb ³ , g/dL	MV	RRT	Compartment syndrome	Outcome
A	M	44	? ⁴	PCR +	-	Yes	Concomitant	Yes	23	Yes	Yes	4 limbs	Alive
B	F	47	? ⁵	PCR +	-	Yes	Concomitant	Yes	19	Yes	Yes	No	Dead
C	M	56	IgG K	-	ChAdOx1	Yes	3d after 1 st dose	Yes	23	No	No	No	Alive
D	M	35	IgG L	PCR +	-	Yes	Concomitant	Yes	25	Yes	Yes	4 limbs	Alive
E	M	38	IgG K	PCR +	-	Yes	Concomitant	Yes	26	Yes	No	Lower limbs	Alive

Abbreviation: COVID-19, the coronavirus disease 2019; M, male; F, female; IgG, G immunoglobulin; K, kappa light chain; L, lambda light chain; PCR, polymerase-chain reaction; d, days; ICU, intensive care unit ; Hb, hemoglobin; MV, mechanical ventilation ; RRT, renal replacement therapy.

¹Interval between COVID-19 infection or COVID-19 vaccination and Clarkson's disease flare

²Admission to the ICU

³Hemoglobin highest value during the episode

⁴Monoclonal gammopathy could not be found during the acute episode and will be tested few weeks/month after the flare

⁵Monoclonal gammopathy could not be found during the acute episode and the patient died